Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of patients with neuromuscular conditions who have rare diseases at the 2025 ...

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

Hultman’s career ended in 2016, after developing the muscular disease myasthenia gravis one year earlier. Hultman dominated ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ ...

The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

Shares of argenx SE ARGX rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART ...

American depositary receipts of Argenx rose after the company received approval from the Food and Drug Administration for a new delivery method of its treatment for some patients with certain ...

Argenx (ARGX) announced that the U.S. Food and Drug Administration approved a new option for patients to self-inject VYVGART Hytrulo with a ...

Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...